Research programme: recombinant antibody mixtures- Symphogen

Drug Profile

Research programme: recombinant antibody mixtures- Symphogen

Alternative Names: Anti-RSV rpAb; Anti-vaccinia virus rpAb; Sym 002; Sym 003; Sym 005; Sym 007; Sym 008

Latest Information Update: 21 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Symphogen
  • Developer Genentech; Symphogen
  • Class Monoclonal antibodies; Polyclonal antibodies; Recombinant proteins
  • Mechanism of Action ERBB 2 receptor modulators; Immunoglobulin stimulants; Immunomodulators; Immunostimulants; Receptor protein-tyrosine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Smallpox
  • Research Infections
  • No development reported Cancer; Hypersensitivity; Respiratory syncytial virus infections

Most Recent Events

  • 09 May 2013 No development reported for Cancer in Denmark (Parenteral)
  • 09 May 2013 Sym 002 is still in preclinical development for Smallpox in Denmark
  • 09 May 2013 Sym 008 is still in early research for Infections in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top